阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的临床疗效和安全性观察

Explore the clinical efficacy and safety of Azithromycin plus Xiaoer Xiaoji Zhike oral solutions in mycoplasma pneumonia children

目的探讨阿奇霉素联合小儿消积止咳口服液治疗小儿支原体肺炎的临床疗效和安全性。方法本次研究以2016年6月~2019年6月收治的62例小儿支原体肺炎患儿作为观察对象,并将其随机分为对照组与联合组各31例,对照组单纯应用阿奇霉素治疗,而联合组在前者基础上采用小儿消积止咳口服液治疗,对比两组患儿干预前后炎性因子的表达水平、临床症状积分,统计两组治疗有效率。结果联合组在治疗效果上优于对照组,差异有统计学意义(P<0.05);联合组患儿在咳嗽、喘憋、哮鸣音以及肺部啰音等症状的消失时间上较对照组更短,组间差异具有统计学意义(P<0.05);治疗前两组患儿各项免疫因子水平相比,差异无统计学意义(P>0.05);治疗后两组患儿IgM、IgA均有所下降,但相比之下,联合组IgM、IgA下降更为显著(P<0.05),其余指标对比差别无统计学意义(P>0.05);对比用药后不良反应发现,对照组与联合组的不良反应发生率分别为9.68%与12.90%,经统计学检查差异无统计学意义(P>0.05)。结论在阿奇霉素的用药基础上配合小儿消积止咳口服液治疗不仅显著提高疗效,同时也未增加用药不良反应,是临床治疗小儿支原体肺炎的可靠选择。

Objective To explore the clinical efficacy and safety of Azithromycin plus Xiaoer Xiaoji Zhike oral solutions in mycoplasma pneumonia children.Methods 62 mycoplasma pneumonia children treated from June 2016 to June 2019 in our hospital were chosen and randomly classified into control group(31 cases,Azithromycin)and combined group(31 cases,Azithromycin plus Xiaoer Xiaoji Zhike oral solutions).Inflammatory factor levels,symptom scores and total effective rate were counted.Results Treatment outcomes in combined group were better than control group(P<0.05);disappearance time of cough,dyspnea,wheezing rale and lung rale in combined group was significantly shorter than control group(P<0.05);before treatment,inflammatory factors between groups were not significantly different(P>0.05);after 2 w of treatment,IgM and IgA levels in combined group were even lower than control group(P<0.05);other indicators between groups were not significantly different(P>0.05);adverse event rate in control group(9.68%)and combined group(12.90%)was not significantly different(P>0.05).Conclusion Azithromycin combined with Xiaoer Xiaoji Zhike oral solutions can improve the treatment outcomes and produce no effects on adverse reactions.